Media coverage about Global Blood Therapeutics (NASDAQ:GBT) has been trending somewhat positive on Tuesday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.8787430554011 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- FY2017 Earnings Forecast for Global Blood Therapeutics Inc (GBT) Issued By Oppenheimer (americanbankingnews.com)
- Global Blood Therapeutics Inc Expected to Earn FY2022 Earnings of $4.30 Per Share (GBT) (americanbankingnews.com)
- Global Blood Therapeutics Inc (GBT) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
- Global Blood Therapeutics Stock Breaks Out, These Are the Implications (profitconfidential.com)
- Peter Radovich Sells 15,000 Shares of Global Blood Therapeutics Inc (GBT) Stock (americanbankingnews.com)
Global Blood Therapeutics (GBT) opened at $56.60 on Tuesday. Global Blood Therapeutics has a 12 month low of $14.70 and a 12 month high of $57.75. The stock has a market cap of $2,604.02, a price-to-earnings ratio of -22.20 and a beta of 4.24.
A number of research firms have issued reports on GBT. HC Wainwright set a $73.00 target price on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 11th. BidaskClub lowered shares of Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 20th. Wedbush restated an “outperform” rating and set a $73.00 price target on shares of Global Blood Therapeutics in a research note on Friday, December 15th. Needham & Company LLC increased their price target on shares of Global Blood Therapeutics from $51.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, December 14th. Finally, Oppenheimer set a $79.00 price target on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and fourteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $62.07.
In other Global Blood Therapeutics news, Director Charles J. Homcy sold 70,000 shares of the stock in a transaction on Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now directly owns 83,328 shares of the company’s stock, valued at approximately $2,830,652.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Peter Radovich sold 12,500 shares of the stock in a transaction on Monday, October 30th. The shares were sold at an average price of $35.00, for a total transaction of $437,500.00. Following the completion of the sale, the vice president now directly owns 2,684 shares of the company’s stock, valued at $93,940. The disclosure for this sale can be found here. Over the last three months, insiders sold 100,500 shares of company stock valued at $3,675,050. Insiders own 5.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/global-blood-therapeutics-gbt-earns-daily-media-impact-score-of-0-18/1819618.html.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with our FREE daily email newsletter.